Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab mafodotin + dexamethasone
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Belantamab mafodotin + dexamethasone is an investigational combination therapy being studied for the treatment of primary immune thrombocytopenia (ITP). Belantamab mafodotin (Blenrep) is a first-in-class antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), a protein highly expressed on plasma cells. It consists of a humanized IgG1 monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF) via a non-cleavable maleimidocaproyl linker. By depleting BCMA-positive plasma cells, it aims to reduce the production of pathogenic autoantibodies in ITP. Dexamethasone is a potent glucocorticoid used to further suppress the immune response. This combination is currently being evaluated in a Phase II trial sponsored by the Hellenic Society of Hematology for adult patients with ITP who have failed prior treatments like TPO receptor agonists or rituximab.
- Other names
- belantamab mafodotin-blmf
02
Targets
BCMA (B-cell maturation antigen)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on belantamab mafodotin + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab mafodotin + dexamethasone.